Diabetes Mellitus — Epidemiology & Control

Diabetes mellitus (DM) is the prototype non-communicable disease (NCD) for Community Medicine — examiners love its exact diagnostic cut-offs, the India-specific prevalence story (the "diabetes capital" tag), and the NPCDCS programme structure. This note packs the numbers, criteria, and control strategy you must reproduce verbatim in the exam.

Definition & classification

Diabetes mellitus is a chronic metabolic disorder characterised by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both, leading to disturbances of carbohydrate, fat, and protein metabolism. Chronic hyperglycaemia is associated with long-term microvascular and macrovascular damage.

WHO/ADA aetiological classification:

Type	Basis	Key features
Type 1 DM	Autoimmune β-cell destruction → absolute insulin deficiency	Young onset, ketosis-prone, anti-GAD/IA-2 antibodies, ~5–10% of cases
Type 2 DM	Insulin resistance + relative insulin deficiency	Adult/older onset (now in youth too), obesity-linked, ~90% of cases
Gestational DM (GDM)	Glucose intolerance first recognised in pregnancy	Resolves post-partum, predicts future T2DM
Other specific types	MODY, pancreatic disease, drug-induced (steroids), endocrinopathies	"Secondary diabetes"

High-yield: Type 2 DM accounts for roughly 90% of all diabetes worldwide and is the form that dominates community-medicine and NCD discussions. India's burden is overwhelmingly T2DM.

The natural history runs through a pre-diabetes stage — impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) — which is the prime target window for community-level prevention.

Epidemiology — global & India

Diabetes is rising fastest in low- and middle-income countries. The IDF Diabetes Atlas estimates roughly half a billion adults (20–79 years) living with diabetes globally, projected to climb steeply by 2045, with the largest absolute numbers in the Western Pacific, South-East Asia, and the Middle East/North Africa regions.

India-specific facts (high-yield):

• India has among the highest absolute number of people with diabetes in the world — historically dubbed the "Diabetes Capital of the World."
• The landmark ICMR–INDIAB study (Indian Council of Medical Research – India Diabetes) is the national reference for prevalence. It documented marked urban–rural and inter-state variation, with higher prevalence in southern and more economically developed states and a large pool of pre-diabetes (often exceeding the diabetes pool itself).
• A large proportion of Indian diabetics are undiagnosed ("rule of halves" pattern), and Indians develop diabetes a decade earlier and at lower BMI than Western populations — the "Asian Indian phenotype" (central/visceral adiposity, higher body fat at lower BMI, early β-cell failure).

High-yield: Remember the "Asian Indian phenotype" — thin-fat Indian, central obesity, high insulin resistance, younger age of onset, lower BMI threshold. This explains India's revised lower BMI cut-offs (overweight ≥23, obesity ≥25 kg/m²).

Risk factors

Non-modifiable

• Age (risk rises with age), family history/genetics, ethnicity (South Asians at high risk).
• Previous GDM or delivery of a macrosomic baby (>4 kg).
• History of IFG/IGT (pre-diabetes).

Modifiable

• Obesity, especially central/abdominal obesity (raised waist circumference, high waist-hip ratio).
• Physical inactivity / sedentary lifestyle.
• Unhealthy diet — energy-dense, refined carbohydrate, high saturated fat, low fibre.
• Hypertension, dyslipidaemia (the metabolic syndrome cluster).
• Tobacco and harmful alcohol use, psychosocial stress.
• Low birth weight / intrauterine growth restriction → Barker hypothesis (foetal origins of adult disease), relevant for India's developmental programming of T2DM.

High-yield: Central obesity (visceral fat) is a stronger predictor of T2DM than generalised obesity in Indians. Asian-specific waist cut-offs: men ≥90 cm, women ≥80 cm.

Diagnostic criteria (WHO) — the most tested area

Diabetes can be diagnosed by any one of the following (a single abnormal value should be confirmed on a repeat test in asymptomatic individuals):

Test	Diabetes (cut-off)	Pre-diabetes
Fasting plasma glucose (FPG)	≥126 mg/dL (7.0 mmol/L)	IFG: 110–125 mg/dL (WHO); ADA uses 100–125
2-hour plasma glucose (75 g OGTT)	≥200 mg/dL (11.1 mmol/L)	IGT: 140–199 mg/dL (7.8–11.0 mmol/L)
HbA1c	≥6.5% (≥48 mmol/mol)	5.7–6.4% (pre-diabetes, ADA); 6.0–6.4% per WHO
Random plasma glucose	≥200 mg/dL + classic symptoms	—

Definitions to memorise precisely:

• Fasting = no caloric intake for at least 8 hours.
• OGTT uses a 75 g anhydrous glucose load (1.75 g/kg, max 75 g, in children) dissolved in water; plasma glucose measured at 2 hours.
• Impaired Fasting Glucose (IFG): FPG 110–125 mg/dL AND 2-h OGTT <140 mg/dL (WHO).
• Impaired Glucose Tolerance (IGT): 2-h OGTT 140–199 mg/dL AND FPG <126 mg/dL.

High-yield triad to recite: FPG ≥126 · 2-h OGTT ≥200 · HbA1c ≥6.5% (plus random ≥200 with symptoms). These four are the WHO/ADA diagnostic anchors — the single most repeated MCQ in NCD epidemiology.

Diagnostic flow: At-risk/symptomatic person → measure FPG (or HbA1c) → if FPG ≥126 or HbA1c ≥6.5% → confirm with repeat test (if asymptomatic) → if equivocal/intermediate, do 75 g OGTT → classify as normal / pre-diabetes / diabetes.

HbA1c caveats (commonly tested): HbA1c is unreliable in anaemia, haemoglobinopathies (HbS, HbE, thalassaemia), pregnancy, recent blood transfusion, chronic kidney disease, and conditions altering red cell turnover. In such settings rely on FPG/OGTT. HbA1c reflects average glycaemia over the preceding ~2–3 months (RBC lifespan ~120 days).

Gestational diabetes mellitus (GDM) — screening criteria

GDM is glucose intolerance with onset or first recognition during pregnancy. India follows a universal screening approach because of its very high baseline risk.

DIPSI (Diabetes in Pregnancy Study Group of India) test — Govt. of India endorsed:

• Give 75 g oral glucose irrespective of the last meal (non-fasting, single step).
• Measure plasma glucose at 2 hours.
• 2-h value ≥140 mg/dL → diagnose GDM. (≥200 mg/dL = overt diabetes in pregnancy.)
• Simple, field-friendly, one-step — ideal for the Indian community/antenatal setting.

IADPSG / WHO 2013 criteria (75 g OGTT, fasting): any one abnormal value diagnoses GDM —

Time	Threshold
Fasting	≥92 mg/dL
1 hour	≥180 mg/dL
2 hours	≥153 mg/dL

High-yield: For Indian community-medicine answers, the DIPSI single-step 75 g, non-fasting, 2-h ≥140 mg/dL criterion is the key fact. Screening is recommended at the first antenatal visit and repeated at 24–28 weeks if initially normal.

GDM increases risk of macrosomia, neonatal hypoglycaemia, pre-eclampsia, polyhydramnios, and a high lifetime maternal risk of subsequent T2DM.

Pathophysiology in brief

• T1DM: Autoimmune (T-cell mediated) destruction of pancreatic β-cells → absolute insulin deficiency → unrestrained lipolysis and ketogenesis → DKA-prone.
• T2DM: Insulin resistance (skeletal muscle, liver, adipose) precedes and coexists with progressive β-cell dysfunction; relative insulin deficiency develops over years. Hyperglycaemia itself worsens both (glucotoxicity, lipotoxicity).
• Chronic hyperglycaemia drives complications via the polyol pathway, advanced glycation end-products (AGEs), protein kinase C activation, and hexosamine pathway, plus oxidative stress and endothelial dysfunction.

Clinical features

• Classic symptoms: polyuria, polydipsia, polyphagia, unexplained weight loss (the "3 Ps + weight loss"), fatigue, blurred vision.
• T2DM is frequently asymptomatic and detected on screening or when a complication (e.g., non-healing ulcer, recurrent infections, neuropathy) presents.
• Acute emergencies: diabetic ketoacidosis (DKA) (more T1DM) and hyperosmolar hyperglycaemic state (HHS) (more T2DM, elderly).

Complications

Microvascular	Macrovascular	Others
Retinopathy (leading cause of preventable adult blindness)	Coronary artery disease	Diabetic foot / ulcers, amputations
Nephropathy (leading cause of ESRD/CKD)	Stroke / cerebrovascular disease	Recurrent infections, poor wound healing
Neuropathy (peripheral, autonomic)	Peripheral arterial disease	Erectile dysfunction, cataract, periodontitis

High-yield: Diabetic retinopathy is a leading cause of preventable blindness in adults; nephropathy is a leading cause of end-stage renal disease; the diabetic foot is the commonest cause of non-traumatic lower-limb amputation. Earliest detectable sign of nephropathy is microalbuminuria (30–300 mg/day).

Management & drug of choice (overview)

Community-medicine answers emphasise lifestyle as first-line plus pharmacotherapy targets.

• Lifestyle modification first: medical nutrition therapy, ≥150 min/week of moderate physical activity, weight reduction, tobacco cessation. Pre-diabetes is managed primarily by lifestyle (proven to cut progression to T2DM).
• First-line drug for T2DM: Metformin (a biguanide) — unless contraindicated (significant renal impairment, eGFR <30). It is the drug of choice because it reduces insulin resistance, is weight-neutral, and is cheap.
• T1DM & GDM not controlled by diet: Insulin is the mainstay; insulin is the preferred agent in pregnancy.
• Glycaemic targets (general): HbA1c <7% for most adults (individualised); manage BP and lipids aggressively, plus annual foot, eye (fundus), and renal (urine albumin) screening.

NPCDCS — the diabetes control programme

The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) is the flagship NCD programme (now subsumed/strengthened under the broader NP-NCD). Launched 2010, integrated with the National Health Mission (NHM).

Objectives: prevent and control common NCDs through behaviour change, early diagnosis (opportunistic and population-based screening), management, and capacity building, with infrastructure at district and sub-district levels.

Service delivery / structure (high-yield):

• NCD Clinics at District Hospital and CHC level — diagnosis, management, referral.
• District NCD Cell for coordination; Cardiac Care Units / day-care facilities at district hospitals.
• Population-based screening of all individuals ≥30 years for hypertension, diabetes, and three common cancers (oral, breast, cervix), delivered through the sub-centre / Health & Wellness Centres (Ayushman Bharat) and frontline workers (ASHA, ANM, MPW) using the CBAC (Community Based Assessment Checklist) form.
• Diabetes screening field tool: random/fasting capillary blood glucose at HWCs; confirmed cases enrolled and followed up.

High-yield: Under NPCDCS / NP-NCD, population-based NCD screening starts at age 30 years, uses the CBAC checklist, and is anchored at Health & Wellness Centres. Diabetes is screened alongside hypertension and the three common cancers.

Levels of prevention (community framing)

• Primordial: prevent emergence of risk factors — healthy public policy, food labelling, promoting physical activity from childhood.
• Primary: health promotion + specific lifestyle intervention in high-risk/pre-diabetes individuals (diet, exercise, weight loss) → prevents incidence.
• Secondary: early detection by screening (≥30 yr) and prompt treatment to prevent complications.
• Tertiary: disability limitation and rehabilitation — foot care, retinopathy laser/anti-VEGF, dialysis/transplant for nephropathy.

Key differentials

• DM vs renal glycosuria: glycosuria with normal blood glucose (low renal threshold) — diagnose with blood glucose, not urine.
• T1DM vs T2DM: age of onset, body habitus, ketosis, C-peptide (low in T1DM), autoantibodies (positive in T1DM).
• Stress/secondary hyperglycaemia: sepsis, steroids, Cushing's, pancreatitis — exclude before labelling primary diabetes.
• Diabetes insipidus: polyuria/polydipsia but normal blood glucose, dilute urine, ADH-related — do not confuse with mellitus.

Recently asked / exam angle

• Exact WHO cut-offs: FPG ≥126 mg/dL, 2-h OGTT ≥200 mg/dL, HbA1c ≥6.5%, random ≥200 mg/dL with symptoms — recur almost every year. Know the mmol/L equivalents too (7.0 / 11.1).
• IFG vs IGT ranges — distinguish WHO IFG (110–125) from ADA IFG (100–125); IGT 140–199 mg/dL on OGTT.
• GDM screening: DIPSI single-step 75 g non-fasting, 2-h ≥140 mg/dL; and IADPSG fasting ≥92 / 1-h ≥180 / 2-h ≥153.
• NPCDCS: launch year (2010), screening age (30 years), CBAC checklist, Health & Wellness Centre delivery, the diseases covered.
• OGTT glucose load (75 g) and the fasting duration (8 hours) are favourite one-liners.
• HbA1c reflects 2–3 months, unreliable in haemoglobinopathy/anaemia/pregnancy.
• Asian Indian phenotype and revised Indian BMI/waist cut-offs (BMI ≥23 overweight; waist M ≥90, F ≥80 cm).
• Diabetic retinopathy = preventable blindness; nephropathy = ESRD; microalbuminuria = earliest nephropathy marker.

Mnemonic for diagnostic numbers — "1-2-6 / 2-0-0 / 6.5": FPG 126, OGTT 200, HbA1c 6.5. For complications, "NRN" — Nephropathy, Retinopathy, Neuropathy (the microvascular trio).

Rapid revision

1. FPG ≥126 mg/dL (≥7.0 mmol/L) after ≥8 h fasting diagnoses diabetes.
2. 2-h post 75 g OGTT ≥200 mg/dL (≥11.1 mmol/L) = diabetes; 140–199 = IGT.
3. HbA1c ≥6.5% diagnoses diabetes; reflects glycaemia over the past 2–3 months; unreliable in anaemia/haemoglobinopathy/pregnancy.
4. Random plasma glucose ≥200 mg/dL + classic symptoms = diabetes.
5. IFG (WHO): FPG 110–125 mg/dL; IGT: 2-h OGTT 140–199 mg/dL — both are pre-diabetes, the target for primary prevention.
6. GDM (DIPSI): 75 g glucose, non-fasting, single-step, 2-h ≥140 mg/dL; IADPSG fasting ≥92 / 1-h ≥180 / 2-h ≥153 mg/dL.
7. Type 2 DM ≈ 90% of cases; India = high absolute burden, large undiagnosed pool, Asian Indian phenotype.
8. Metformin is the first-line drug of choice for T2DM; insulin is the mainstay for T1DM and preferred in pregnancy.
9. NPCDCS launched 2010 under NHM; population screening from age 30 using the CBAC checklist at Health & Wellness Centres.
10. Microvascular complications = retinopathy (blindness), nephropathy (ESRD), neuropathy; microalbuminuria is the earliest nephropathy sign.
11. Indian cut-offs: BMI ≥23 = overweight, ≥25 = obese; waist M ≥90, F ≥80 cm; central obesity is the key T2DM driver.
12. HbA1c target <7% for most adults; lifestyle modification is first-line for pre-diabetes and all T2DM.